Nasus Pharma (NSRX)
Develops powder-based nasal drugs for acute medical emergencies.
$3.77
At close−0.05 (−1.44%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Insiders3 holders · as of Nov 13, 2025 | 60.07% | 5.17M shares | |
| Strategic holders1 holder · as of Aug 20, 2025 | 6.68% | 575.1K shares | |
| Otherremainder | 33.25% | 2.86M shares |
8.61M company shares as of Aug 22, 2026 · holders as of their latest filing
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Udi Gilboa | 21.10% | 1.90M | 13G | Nov 10, 2025 ↗ |
| Dr. Dalia Megiddo | 20.90% | 1.89M | 13G | Nov 12, 2025 ↗ |
| Dr. Ronnie Hershman | 15.30% | 1.38M | 13G | Nov 13, 2025 ↗ |
| Balyasny Asset Management L.P. | 9.99% | 1.17M | 13G | May 15, 2026 ↗ |
| Capital Point Ltd. | 6.35% | 575.1K | 13G | Aug 20, 2025 ↗ |
| Funicular Funds, LP | 5.20% | 612.9K | 13G | Apr 7, 2026 ↗ |
Insider tradesForm 4
Latest trades
Nothing filed in the last 12 months.
CongressHouse and Senate disclosures
Not reported.